Categories for Uncategorized

Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study

11 septembra, 2020 7:51 pm Published by m.popovic@wemakemedia.cz

Program: Oral and Poster Abstracts Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II ...

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

11 septembra, 2020 7:51 pm Published by m.popovic@wemakemedia.cz

Program: Oral and Poster Abstracts Type: Oral Session: 642. CLL: Therapy, excluding Transplantation: First Line Treatment Hematology...

Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

11 septembra, 2020 7:51 pm Published by m.popovic@wemakemedia.cz

Program: Oral and Poster Abstracts Type: Oral Session: 642. CLL: Therapy, excluding Transplantation: First Line Treatment Hematology...

ASH® 2019 – B-CLL a indolentné lymfómy

11 septembra, 2020 7:51 pm Published by m.popovic@wemakemedia.cz

61. výročná konferencia ASH priniesla zaujímavé novinky a diskusie aj v oblasti indolentných lymfoproliferácií – indolentných lymfómov (iNHL) a chronickej lymfocytovej leukémie (CLL)....